AMERICAN HEALTH PACKAGING®

Phone: (614) 492-8177
Toll Free Phone: (800) 707-4621

URGENT PRODUCT RECALL
UPDATE – ADDITIONAL LOTS RECALLED – SEE HIGHLIGHTED CELLS BELOW

October 08, 2025

Dear Valued Customer,

American Health Packaging, Inc. is initiating a voluntary drug recall to the **RETAIL LEVEL** for **AHP Sucralfate Tablets, USP, 1 gram, 100 UD; Carton NDC#: 60687-695-01, (Individual Dose NDC: 60687-695-11),** for the lot listed below. Two additional lots have been added to the original letter sent on July 29, 2025.

Product Description	AHP Lot No.	Expiration Date	Ship Dates of Product
AHP Sucralfate Tablets, USP, 1 gram, 100 UD **Carton NDC#: 60687-695-01** **(Individual Dose NDC: 60687-695-11)**	1015038	07/31/2025	10/31/2023 to 11/20/2023
	1015898	09/30/2025	12/05/2023 to 01/02/2024
	1016873	10/31/2025	02/13/2024 to 05/22/2024
	1017392	**01/31/2026**	**01/08/2025 to 05/02/2025**
	1017415	**12/31/2025**	**05/22/2024 to 01/08/2025**
	1023398	07/31/2026	05/01/2025 to 06/16/2025

REASON	Nostrum Laboratories, Inc. filed Chapter 11 bankruptcy on September 30, 2024. In connection with that filing, the company has ceased and shutdown operations and terminated its operational employees at all domestic U.S. sites. Nostrum Labs is initiating a voluntary recall of Sucralfate Tablets USP 1 gram, all lots within expiry, as a result of the closures and discontinuation of its Quality activities. It cannot be guaranteed that any lots of this product that are still within expiry will meet all intended specifications through the labeled shelf life of the product.
PRODUCT INDICATION:	Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination; Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.
HEALTH HAZARD EVALUATION	The discontinuation of Nostrum Labs' quality program means that the Company is unable to assure that this product meets the identity, strength, quality, and purity characteristics that it is purported or represented to possess. While specific risks to patients from use of an adulterated product cannot always be identified or assessed, it is also not possible to rule out patient risks resulting from the use of such a product. Nostrum Labs has not received any reports of adverse events related to this recall.

ACTIONS REQUIRED

1. **Distributors/Pharmacies** - Immediately examine your inventory, quarantine and discontinue distribution of this lot.
2. **Distributors** - Complete the enclosed Business Reply Card even if you do not have any product on hand.
3. **Distributors** – Please pass this Recall Notice on ONLY to pharmacies that received this product lot.
4. **Pharmacies** – If you have units of the affected products/lot in inventory, please contact Sedgwick at (888) 965-5798 to receive a notification package with the Business Reply Card and return instructions.
5. Business Reply Cards can be submitted by any of these methods.
   Fax: (888) 965-6137
   Email: AHP5183@sedgwick.com
   Mail: 2670 Executive Dr., Ste. A, Indianapolis, IN 46241
6. **Distributors** - Return recalled product to Sedgwick as instructed in recall/return packet.
7. **Pharmacies** - You do not need to contact any patients.

OTHER	This Recall extends to the Retail Level only. No other lots, packages, or formulations are being recalled. Please reorder stock immediately. For questions about the recall process, call Sedgwick at 888-965-5798. This recall is being conducted with the knowledge of the Food and Drug Administration. We appreciate your immediate attention and cooperation and sincerely regret any inconvenience caused by this action.

To receive credit, the reply form and recalled product must be returned to Sedgwick by January 31, 2026.

Thank you for your support in complying with the requests in this letter. We apologize for the inconvenience that this incident may cause you or your customers.

Sincerely,

Becky A Mahon

Becky Mahon (Oct 7, 2025 10:35:50 EDT)

Becky A Mahon
Sr. Manager, Regulatory Affairs and Stability
American Health Packaging

2025-10-08 Sucralfate Tabs Recall Letter (Nostrum) - Retail

Final Audit Report 2025-10-07

Created:	2025-10-07
By:	CHRISTOPHER CRAWFORD (CCRAWFORD@AMERICANHEALTHPACKAGING.COM)
Status:	Signed
Transaction ID:	CBJCHBCAABAAW3fxaVWixCd-AykNWT7mkVLS13z6uTt8

"2025-10-08 Sucralfate Tabs Recall Letter (Nostrum) - Retail" History

Document created by CHRISTOPHER CRAWFORD (CCRAWFORD@AMERICANHEALTHPACKAGING.COM)
2025-10-07 - 1:56:23 PM GMT

Document emailed to Becky Mahon (BMahon@americanhealthpackaging.com) for signature
2025-10-07 - 1:58:01 PM GMT

Email viewed by Becky Mahon (BMahon@americanhealthpackaging.com)
2025-10-07 - 2:31:23 PM GMT

Document e-signed by Becky Mahon (BMahon@americanhealthpackaging.com)
Signature Date: 2025-10-07 - 2:35:50 PM GMT - Time Source: server

Agreement completed.
2025-10-07 - 2:35:50 PM GMT